Cullinan Oncology Announces US FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing Il-2 and Il-12 Cytokines

Cullinan Oncology, Inc. announced the US FDA has cleared its Investigational New Drug application for CLN-617, a fusion protein comprised of two potent and synergistic antitumor cytokines, IL-2 and IL-12, with a collagen binding domain designed for retention in the tumor microenvironment following intratumoral injection.